Investors, mark your calendars! The much-anticipated Innova Captab IPO, with a face value of ₹10 per equity share and a price band of ₹426 to ₹448 per share, is set to open on December 21, 2023. This comprehensive guide not only provides key details but also offers a unique perspective on why this IPO, aiming to raise ₹570 Crores, is creating a buzz.
Innova Captab IPO Essentials: GMP, Dates, Quotas, and More
The IPO, closing on December 26, 2023, caters to various investor preferences with a retail quota of 35%, QIB at 50%, and HNI at 15%. Stay tuned for the latest GMP (Grey Market Premium) updates, ensuring you make informed decisions.
| Key Details | Values |
|---|---|
| IPO Opening Date | December 21, 2023 |
| IPO Closing Date | December 26, 2023 |
| IPO Size | ₹570 Crores |
| Fresh Issue | ₹320 Crores |
| Offer for Sale | 5,580,357 shares |
| Face Value | ₹10 per Equity Share |
| Price Band | ₹426 to ₹448 per Share |
| IPO Listing Date | December 29, 2023 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| IPO Allotment Date | December 27, 2023 |
| GMP (Grey Market Premium) | 100 (22%) |
A Glimpse into Innova Captab’s Pharmaceutical Empire
Innova Captab isn’t just another pharmaceutical company; it’s a powerhouse with a robust presence across the pharmaceutical value chain. From research and development to manufacturing, distribution, and global exports, Innova Captab’s integrated approach sets it apart.
Diverse Product Portfolio: Beyond Medicines
The company’s product portfolio is a testament to its commitment to diverse healthcare solutions. From cephalosporins to cardiovascular medications, Innova Captab’s offerings cater to a broad spectrum of therapeutic areas.
Financial Triumphs: Beyond Numbers
In the competitive landscape of pharmaceutical formulation CDMO players, Innova Captab emerged as a force to be reckoned with in Fiscal 2022. Ranking third in operating revenue, second in operating profit margin, third in net profit margin, and second in return on capital employed, the company’s financial triumphs tell a compelling story.
Valuation Insights – FY2023
Evaluating Innova Captab’s performance in FY2023 reveals an Earning Per Share (EPS) of ₹14.16, a robust Return on Net Worth (RoNW) of 24.58%, and a Net Asset Value (NAV) of ₹57.60 per Equity Share.
Peer Group Comparison: Standing Among Giants
Innova Captab stands tall among its peers, including Torrent Pharmaceuticals Limited, Laurus Labs Limited, Ajanta Pharma Limited, and others. This peer group comparison gives you valuable insights into the company’s positioning in the industry.
IPO Application: Simplified for You
Curious about how to apply for Innova Captab IPO? We’ve got you covered. Whether it’s Zerodha, Upstox, or Paytm Money, we provide step-by-step instructions to make the application process a breeze.
FAQs – Your Queries, Answered
Still, have questions? Our FAQs section covers everything from IPO size and allotment date to listing date and investor portions. Get the answers you need to make informed decisions.
Contact and Connectivity
As the curtain rises on Innova Captab IPO, embark on this journey armed with knowledge and a unique perspective. This guide is crafted not just to inform but to engage and empower you, ensuring your investment decisions are backed by insightful data and a genuine understanding of the opportunities that lie ahead. Get ready to be a part of something extraordinary!